Clinical registry collecting real-world evidence on wound care treatments (SIDDX)

ISRCTN ISRCTN96261955
DOI https://doi.org/10.1186/ISRCTN96261955
ClinicalTrials.gov number NCT06328010
Secondary identifying numbers Pro00070536
Submission date
06/06/2024
Registration date
18/06/2024
Last edited
26/07/2024
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Injury, Occupational Diseases, Poisoning
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
This study will collect data on various wound treatments and their related wound-healing processes in real-life settings.

Who can participate?
All adults requiring wound care

What does the study involve?
Continuation of wound treatment as dictated by the treating physician

What are the possible benefits and risks of participating?
It is hoped that these results will help future participants benefit from an improved wound treatment regime and healing times. Possible risks are allergic or autoimmune response to the biological/synthetic grafts used, since we are strictly observing treatments, the treating providers will be strongly requested to observe for such an incident and report AE/SAE. All products observed are mandated to have FDA clearance, as such risk to the patient is minimal.

Where is the study run from?
Siddhey LLC (United States of America)

When is the study starting and how long is it expected to run for?
April 2024 to March 2029

Who is funding the study?
Siddhey LLC (United States of America)

Who is the main contact?
Mr Chinmay Chauhan (MBA, RN-BSN, BSBE), ChinmayC@siddhey.com

Contact information

Mr Chinmay Chauhan
Public, Scientific, Principal Investigator

215 E Warm Springs Rd, STE 108
Las Vegas
89119
United States of America

Phone +1 2245581092
Email chinmayc@siddhey.com

Study information

Study designMulticenter observational study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Care home, GP practice, Home, Hospital, Medical and other records, University/medical school/dental school
Study typeQuality of life, Treatment, Efficacy
Participant information sheet 45580_PIS_08Jan0824.pdf
Scientific titleAn observational clinical registry to collect safety and efficacy data on wound care treatments from a variety of treatment settings
Study acronymSIDDX
Study objectivesThe study's primary objection is to collate an observational clinical registry to collect treatment outcomes after biological and synthetic amnion grafts. It is hypothesised that wound treatment will reduce healing time by >40%
Ethics approval(s)

Approved 27/09/2023, Advarra IRB (6100 Merriweather Dr., Suite 600, Columbia, MD 21044, United States of America; +1 877-992-4724; adviser@advarra.com), ref: SIDDXAC02

Ethics approval additional informationThe study will not challenge the treatment practice of physicians treating wound (+), and will only collect data on treatment which has been agreed upon by the physician and patients.
Health condition(s) or problem(s) studiedImproving heal rate in wound care
InterventionThis is a multicenter observational study enrolling deidentified patients that will collect data on the healing rate of wounds and wound care between the standard of care and many advanced therapeutic interventions.

Physicians, APRNs, and PAs treating patients for any type of "wound" care resulting from conditions such as diabetes, vascular insufficiency, dermatological conditions, or from trauma, surgical/post-surgical events, chemotherapy, burns, and degloving will be observed. The two treatment methods observed will be standard of care (SOC) and treatment with biological or synthetic grafts (advanced treatment modality). The timeframe of 12 weeks (1/week 10 treatment = 10 weeks and 2 weeks post closure/end of 10 weeks follow up) at maximum will be observed. This data will be analyzed to determine the rate of healing via the use of advanced treatment modalities. Since the observational study will not dictate therapy, and very few IC/EC this will be as close to real-world evidence data that can be gathered.
Intervention typeBiological/Vaccine
Pharmaceutical study type(s)Not Applicable
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Acesso, NeoStim, Surgraft biological/synthetic grafts
Primary outcome measureThe rate of wound healing measured using data documented during every treatment visit (once per week), first is 20% healed, next is 50% compared to week 1, and lastly 100%
Secondary outcome measuresThe rate of wound healing measured using data collected every week for a maximum of 10 weeks to achieve wound closure (100%), based on the assumption of one treatment (encounter) per week
Overall study start date14/02/2023
Completion date31/03/2030

Eligibility

Participant type(s)Patient, Population
Age groupAdult
Lower age limit21 Years
SexBoth
Target number of participants4000
Key inclusion criteria1. Aged ≥18 years of age
2. Ulcer or a chronic wound, including an ulcer (diabetic foot ulcer, venous stasis ulcer, etc.), injury (trauma, post-surgical, Mohs surgery treatment), burns injury, and acute/chronic wounds
3. Subject agrees to the use of his health data, including photos of his wound in analysis and publications
4. The subject/subject's legally authorised representative (LAR) must be able to read and understand English and/or Spanish
Key exclusion criteriaThe subject/subject's legally authorised representative (LAR) is unable to read and understand English or Spanish.
Date of first enrolment01/04/2024
Date of final enrolment30/06/2029

Locations

Countries of recruitment

  • United States of America

Study participating centre

Dr Brian Evans
7325 Medical Center Drive, Suite 304
West Hills
91307
United States of America

Sponsor information

Siddhey LLC
Research organisation

215 E Warm Springs Rd, STE 108
Las Vegas
89119
United States of America

Phone None provided
Email chinmayc@siddhey.com
Website https://www.siddhey.com

Funders

Funder type

Industry

Siddhey LLC

No information available

Results and Publications

Intention to publish date14/10/2024
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planCurrent plan is to perform QUARTERLY publications starting October 2024, leading up to interim analysis reports at 250 patient marks.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Mr Chinmay Chauhan (MBA, RN-BSN, BSBE), ChinmayC@siddhey.com. IPD and analytics will be stored in a secured web server located at https://www.siddhey.com and will only be made available to contracted manufacturers and any healthcare governing bodies.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet 08/01/2008 18/06/2024 No Yes
Protocol file 27/09/2023 18/06/2024 No No
Other files Informed Consent Form 10/07/2024 16/07/2024 No No

Additional files

45580_Protocol_27sept2023.pdf
45580_PIS_08Jan0824.pdf
ISRCTN96261955_ICF_10Jul24.pdf
Informed Consent Form

Editorial Notes

26/07/2024: Internal review.
16/07/2024: The following changes were made to the study record:
1. Informed consent form uploaded.
2. The public title was changed from 'A registry to collect data on wound care in medical centers' to 'Clinical registry collecting real-world evidence on wound care treatments (SIDDX)'.
3. The scientific title was changed from 'An observational clinical registry to collect safety and efficacy data on wound care in medical centers' to 'An observational clinical registry to collect safety and efficacy data on wound care treatments from a variety of treatment settings'.
17/06/2024: Study's existence confirmed by the Advarra Center for IRB Intelligence (CIRBI) Platform.